{"id":"NCT02614261","sponsor":"Eli Lilly and Company","briefTitle":"Evaluation of Galcanezumab in the Prevention of Chronic Migraine","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-30","primaryCompletion":"2017-03-16","completion":"2021-07-14","firstPosted":"2015-11-25","resultsPosted":"2019-01-07","lastUpdate":"2022-05-18"},"enrollment":1117,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Migraine"],"interventions":[{"type":"DRUG","name":"Galcanezumab","otherNames":["LY2951742"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Galcanezumab 120 mg","type":"EXPERIMENTAL"},{"label":"Galcanezumab 240 mg","type":"EXPERIMENTAL"},{"label":"Israel Addendum","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.","primaryOutcome":{"measure":"Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHD)","timeFrame":"Baseline, Month 1 through Month 3","effectByArm":[{"arm":"Placebo","deltaMin":-2.74,"sd":0.36},{"arm":"Galcanezumab 120mg","deltaMin":-4.83,"sd":0.44},{"arm":"Galcanezumab 240mg","deltaMin":-4.62,"sd":0.43}],"pValues":[{"comp":"OG000 vs OG001","p":"<.001"},{"comp":"OG000 vs OG002","p":"<.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":117,"countries":["United States","Argentina","Canada","Czechia","Germany","Israel","Italy","Mexico","Netherlands","Puerto Rico","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["39901101","35392739","35076090","34264500","33950375","33549036","33544305","33143451","33069214","32930994","32576229","31952501","31482569","31104507","30594122","30462830","30446596"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/FnCyu97viesEckigw4wmc"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":558},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Injection site reaction","Injection site pain","Urinary tract infection"]}}